Pfizer fronts $250M to nab antisense drug from Akcea/Ionis in up to $1.5B deal
Earlier this year, Pfizer secured early approval of its touted blockbuster — tafamidis — for transthyretin-mediated amyloidosis, a field initially divided between Alnylam and Akcea/Ionis. Now the big drugmaker is licensing an antisense therapy for certain cardiovascular and metabolic diseases from its smaller rival.
Under the agreement, Akcea $AKCA and its sister company Ionis $IONS — which owns a controlling interest in its stock — will receive $250 million upfront, and up to $1.3 billion in milestone payments, in addition to double-digit royalties.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.